| |
| |
| Exchange: |
American Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
49,160,000 |
| Market
Cap: |
354.94(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$2.14 - $13.81 |
|
| Level
I Sector: |
Financials |
| Level
II Sector: |
Financial Services |
| Level
III Sector: |
Diversified Investments |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. Co.'s primary product candidate, pemvidutide (proposed INN), is a good laboratory practices-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and non-alcoholic steatohepatitis. In addition, Co. is developing HepTcell, an immunotherapeutic agent designed to achieve a functional cure for chronic hepatitis B.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
300 |
31,500 |
| Total Buy Value |
$0 |
$0 |
$863 |
$138,033 |
| Total People Bought |
0 |
0 |
1 |
3 |
| Total Buy Transactions |
0 |
0 |
1 |
6 |
| Total Shares Sold |
0 |
0 |
0 |
155,302 |
| Total Sell Value |
$0 |
$0 |
$0 |
$2,133,902 |
| Total People Sold |
0 |
0 |
0 |
5 |
| Total Sell Transactions |
0 |
0 |
0 |
9 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Jordt Raymond M |
Chief Business Officer |
• – – |
2024-01-01 |
4 |
D |
$11.25 |
$28,159 |
D/D |
(2,503) |
8,704 |
|
- |
|
| Jordt Raymond M |
Chief Business Officer |
• – – |
2024-01-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,375 |
11,207 |
|
- |
|
| Eisenstadt Richard I |
Chief Financial Officer |
• – – |
2023-12-29 |
4 |
D |
$11.25 |
$34,245 |
D/D |
(3,044) |
33,291 |
|
- |
|
| Eisenstadt Richard I |
Chief Financial Officer |
• – – |
2023-12-29 |
4 |
OE |
$0.00 |
$0 |
D/D |
12,500 |
36,335 |
|
- |
|
| Drutz David |
Director |
– • – |
2023-08-15 |
4 |
B |
$2.88 |
$863 |
I/I |
300 |
29,785 |
2.02 |
181% |
|
| Jordt Raymond M |
Chief Business Officer |
• – – |
2023-07-31 |
4 |
A |
$2.81 |
$5,148 |
D/D |
1,832 |
1,832 |
|
- |
|
| Eisenstadt Richard I |
Chief Financial Officer |
• – – |
2023-07-31 |
4 |
A |
$2.81 |
$5,128 |
D/D |
1,825 |
23,835 |
|
- |
|
| Garg Vipin K |
President and CEO |
• • – |
2023-07-31 |
4 |
A |
$2.81 |
$354 |
D/D |
126 |
249,255 |
|
- |
|
| Roberts M Scot |
Chief Scientific Officer |
• – – |
2023-07-31 |
4 |
A |
$2.81 |
$1,596 |
D/D |
568 |
20,424 |
|
- |
|
| Harris Matthew Scott |
Chief Medical Officer |
• – – |
2023-07-31 |
4 |
A |
$2.81 |
$1,942 |
D/D |
691 |
34,002 |
|
- |
|
| Eisenstadt Richard I |
Chief Financial Officer |
• – – |
2023-03-24 |
4 |
B |
$4.31 |
$43,140 |
D/D |
10,000 |
22,010 |
2.74 |
-28% |
|
| Drutz David |
Director |
– • – |
2023-03-23 |
4 |
B |
$4.27 |
$38,430 |
I/I |
9,000 |
29,484 |
2.1 |
-27% |
|
| Harris Matthew Scott |
Chief Medical Officer |
• – – |
2023-03-23 |
4 |
B |
$4.22 |
$42,200 |
D/D |
10,000 |
33,311 |
2.74 |
-27% |
|
| Roberts M Scot |
Chief Scientific Officer |
• – – |
2023-02-02 |
4 |
D |
$15.04 |
$35,720 |
D/D |
(2,375) |
19,856 |
|
- |
|
| Roberts M Scot |
Chief Scientific Officer |
• – – |
2023-02-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,775 |
22,231 |
|
- |
|
| Harris Matthew Scott |
Chief Medical Officer |
• – – |
2023-02-02 |
4 |
D |
$15.04 |
$35,555 |
D/D |
(2,364) |
23,311 |
|
- |
|
| Harris Matthew Scott |
Chief Medical Officer |
• – – |
2023-02-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,775 |
25,675 |
|
- |
|
| Garg Vipin K |
President and CEO |
• • – |
2023-02-02 |
4 |
D |
$15.04 |
$126,667 |
D/D |
(8,422) |
249,129 |
|
- |
|
| Garg Vipin K |
President and CEO |
• • – |
2023-02-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
18,950 |
257,551 |
|
- |
|
| Roberts M Scot |
Chief Scientific Officer |
• – – |
2023-02-01 |
4 |
D |
$13.78 |
$30,082 |
D/D |
(2,183) |
14,456 |
|
- |
|
| Roberts M Scot |
Chief Scientific Officer |
• – – |
2023-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,166 |
16,639 |
|
- |
|
| Harris Matthew Scott |
Chief Medical Officer |
• – – |
2023-02-01 |
4 |
D |
$13.78 |
$30,082 |
D/D |
(2,183) |
17,900 |
|
- |
|
| Harris Matthew Scott |
Chief Medical Officer |
• – – |
2023-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,166 |
20,083 |
|
- |
|
| Garg Vipin K |
President and CEO |
• • – |
2023-02-01 |
4 |
D |
$13.78 |
$105,527 |
D/D |
(7,658) |
238,601 |
|
- |
|
| Garg Vipin K |
President and CEO |
• • – |
2023-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
16,546 |
246,259 |
|
- |
|
260 Records found
|
|
Page 2 of 11 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.50 (6.48%) 
